Title : Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer.

Pub. Date : 2019 Nov 15

PMID : 31515456






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Low AR-active tumors were predicted to be more sensitive to poly (ADP-ribose) polymerase inhibition, platinum chemotherapy, and radiotherapy, and less sensitive to docetaxel and androgen-deprivation therapy. Docetaxel androgen receptor Homo sapiens